Rebirthel Co., Ltd. was founded in October, 2019.
Rebirthel aims to realize cell-based therapies against cancer or other immune-related diseases by using universal
T cells that are regenerated from pluripotent stem cells.
The strategy is based on methods developed by myself, Dr. Hiroshi Kawamoto (Kyoto University).
It has been shown to be effective to transfuse genetically engineered T cells that had originally been collected from patients.
However, such “autologous” settings have faced problems: costly, time-consuming, and dependent on the quality of the T cells themselves (from the patients).
To solve these problems, Rebirthel provides “off-the-shelf T cells” that can be universally used with any patients in an allogeneic setting.
Pluripotent stem cells such as iPS (induced pluripotent stem) cells or ES (embryonic stem) cells have the potential to produce various types of tissues/organs.
Rebirthel has already established a method by which potent killer T cells can be produced in vitro from iPS cells.
Using this method, Rebirthel is now developing a strategy where tumor antigen-specific T cells are mass-produced and transfused to patients as off-the-shelf T cells.
Certain types of T cells play the role of commander of immune cells, while other types serve as strong warriors.
Therefore, if we can produce different types of T cells - such as killer T cells, helper T cells, or regulatory T cells - covering a wide range of target antigens, we can provide therapeutic T cells targeting any kind of disease related to the immune system (e.g. cancer, infectious diseases, autoimmune diseases, allergies, etc.).
Rebirthel opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease.
Kajii-cho, Kamigyo-ku, Kyoto 602-0841 Japan
Rebirthel operationalizes cell-based cancer immunotherapies developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).
Rebirthel will provide “universal” cytotoxic T lymphocytes regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” in cancer immunotherapy.
Rebirthel took over all projects and intellectual properties related to killer T cells.
･Regcell raised 620,000,000 JPY through a third-party allocation of new shares.
･Regcell raised 20,000,000 JPY through a third-party allocation of new shares.
OP9 cell line and its genetically modified derivatives
Rebirthel has succeeded all rights of the OP9 cells from Dr. Hiroaki Kodama (who originally established the OP9 cell line).
You are required to obtain a license from Rebirthel for commercial use of the OP9 cell line or its derivatives.
Rebirthel Co., Ltd. (Rebirthel) announced that it has entered into a strategic alliance agreement with H.U. Group Research Institute G.K. (H.U. Group) on April 1, 2023 to develop next-generation immun...
Rebirthel Co., Ltd. (Rebirthel) announced that it entered into a collaboration research agreement with Kyoto University and Hitachi, Ltd. (Hitachi) on January 6, 2023, for the development of automated...
Rebirthel and Noile-Immune Biotech announce that they have entered into a contract on collaborative research and commercialization of next-generation gene-modified immune cell therapy combining Rebirt...
The 22nd Japan venture Award (JVA) awards ceremony was held on December 8th, 2022. Mr. Masunori Kajikawa, President and COE of Rebirthel, proudly won the Japan Venture Capital Association (JVCA) encou...
Rebirthel participated in the exhibition “Japan Healthcare Venture Summit 2022 (JHVS2022)”, hosted by Health Ministry, Japan, held at PACIFICO Yokohama from October 13th to October 15th, 2022. Our boo...
“Sogyo Techo” is a free distribution medium targeting entrepreneurs. It makes15,000 printed copies and web articles are previewed over 1,200,000 every month.It features company builders who are carryi...
Venture Summit 2022
“Japan Healthcare Venture Summit 2022”, hosted by the Ministry of Health, Labourand Welfare, Japan, will be held at PACIFICO Yokohama from October 12 th toOctober 14 th , 2022, and Rebirthel will run ...
Informa Pharma Intelligence is the Japanese version of Scrips Awards, a worldwide-known award to applaud the essential role that pharmaceutical, biotech, and other alliedindustries play in improving h...
Public Interest Incorporated Foundation KYOTO Industrial Support Organization 21 has announced the names of companies receiving the subsidy for FY 2022. As was the case last year, Rebirthel was select...
HVC Kyoto, Japan’s largest English-spoken pitch event specializing in health care, was held on July 5th, 2022. This event was supported by Japan External Trade Organization (JETRO), Kyoto prefecture, ...
We will not use your personal information for any purpose other than contacting customers.